Sawada et al. [45] and Amant et al. [35] also identified higher HER2 overexpression in CS, i.e., nine of 16 cases (56%), and three of seven cases (43%), respectively, when considering both 2+ and 3+ positivity by immunohistochemistry [32,36]. This evidence concerns the gene ERBB2 and Cowden syndrome 1.